To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. – 1

Overview

To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.

Full Title of Study: “Safety and Tolerability Study of Sublingual Lobeline”

Study Type

  • Study Type: Interventional
  • Study Design
    • Primary Purpose: Diagnostic

Detailed Description

The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.

Interventions

  • Drug: Lobeline

Clinical Trial Outcome Measures

Primary Measures

  • Safety

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy individuals with a body mass index between 18 and 30. – Willing and able to give written consent. – Must have a negative drug test – Females must have a negative pregnancy test prior to study drug administration – Must have no medical contraindications as determined by routine testing Exclusion Criteria:

  • Please contact the site for more information

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • National Institute on Drug Abuse (NIDA)
  • Overall Official(s)
    • Reese Jones, M.D., Principal Investigator, Langley Porter Psychiatric Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.